News & Events

• June 6, 2023
  

  Shaping the Global Innovation and Access Landscape for Better Paediatric Medicines: C-Path Becomes Official Partner of WHO

  Critical Path Institute (C-Path), a leading global nonprofit committed to expediting drug development through the acceleration of regulatory-endorsed solutions, today announced an official partnership with the World Health Organization’s (WHO) Global Accelerator for Paediatric Formulations (GAP-f) project.

• April 25, 2023
  

  C-Path Europe: A Global Vision of Success

  TUCSON, Ariz. and AMSTERDAM, April 26, 2023 — As an organization that generates regulatory-endorsed solutions and methodologies to accelerate drug development, Critical Path Institute (C-Path) today shared a year-in-review of its European-focused activities to advance global regulatory science. “We are pleased with the progress and continued development of our global efforts in the regulatory and...
• February 15, 2023
  

  Airway Therapeutics Joins C-Path’s International Neonatal Consortium

  C-Path today announced that Airway Therapeutics, Inc., (“Airway”) a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, has become a member of its International Neonatal Consortium (INC)

• December 7, 2022
  

  C-Path Receives Data Transfer from Network of Hospitals in Japan

  C-Path has received properly anonymized electronic patient record (EPR) data from three hospitals in the Neonatal Research Network of Japan — Nagano Children’s Hospital, Kyorin University and Osaka General Hospital. The collaboration comes from partnering with leading pediatric neonatologists, Dr. Tomohiko Nakamura, Dr. Kenichiro Hosoi and Dr. Hiroko Iwami at each site, respectively.

• October 6, 2022
  

  C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Alpha-1 Antitrypsin Deficiency

  C-Path today announced that it has recently launched a pre-consortium collaboration with the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER), focused on accelerating medical product development in alpha-1 antitrypsin deficiency (AATD). The FDA announced the pre-consortium today in a statement on its website.